The clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market size has grown exponentially in recent years. It will grow from $0.15 billion in 2025 to $0.18 billion in 2026 at a compound annual growth rate (CAGR) of 20.4%. The growth in the historic period can be attributed to advancements in genome sequencing technologies, the emergence of early gene therapy research initiatives, increasing funding for rare disease research, development of viral vector-based delivery technologies, and expanding academic research in molecular genetics.
The clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market size is expected to see rapid growth in the next few years. It will grow to $0.36 billion in 2030 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period can be attributed to the expansion of personalized medicine and gene-based therapies, increasing regulatory approvals for gene editing treatments, rising clinical trial activity for oncology and genetic disorders, continued advancements in in vivo delivery technologies, and increasing investment in next-generation genome engineering platforms. Major trends in the forecast period include growing adoption of precision gene correction therapies for rare genetic conditions, increasing clinical application of programmable nuclease-based therapeutic platforms, expansion of personalized regenerative medicine pipelines, wider use of advanced delivery vectors for targeted gene editing, and increasing integration of high-fidelity gene editing validation and safety assessment frameworks.
The increasing demand for electronic devices is expected to drive the growth of the chiplets market in the coming years. Electronic devices are products or tools that rely on electronic components and technologies to carry out specific functions. Chiplets offer a flexible, cost-efficient, and scalable approach to designing and manufacturing electronic devices, helping address the increasing complexity and performance requirements of modern technologies. For instance, in May 2023, according to the Japan Electronics and Information Technology Industries Association, a Japan-based trade association, consumer electronics production amounted to $2.17 trillion (¥32,099 million) in May 2023, compared with $1.71 trillion (¥25,268 million) in May 2022. Furthermore, in February 2023, according to Uswitch Limited, a UK-based financial conduct authority, there were 71.8 million mobile connections in the UK beginning in 2022. The UK population is projected to reach 68.3 million by 2025, with 95% of the population, or approximately 65 million people, expected to own a smartphone. Therefore, the rising demand for electronic devices is driving the growth of the chiplets market.
Key companies operating in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market are focusing on developing innovative therapies, such as ex vivo gene-editing therapy, to treat inherited genetic disorders and improve long-term patient outcomes. Ex vivo gene-editing therapy is a treatment approach in which a patient's cells are removed from the body, genetically modified or corrected in a laboratory using gene-editing technologies such as CRISPR/Cas9, and subsequently infused back into the patient to help treat or potentially cure diseases by addressing the underlying genetic defect. For example, in January 2024, Vertex Pharmaceuticals, a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for CASGEVY (exagamglogene autotemcel [exa-cel]) for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older. CASGEVY is a one-time CRISPR/Cas9 gene-edited cell therapy designed to address the underlying genetic cause of TDT and reduce the need for chronic blood transfusions. The approval followed the earlier FDA approval of CASGEVY for sickle cell disease and represented a significant advancement in the use of genome-editing therapeutics for inherited blood disorders. In addition, Vertex established a network of authorized treatment centers across the US to support the administration of CASGEVY to eligible patients requiring specialized stem cell transplantation procedures.
In July 2025, Eli Lilly and Company, a US-based pharmaceutical and healthcare company, acquired Verve Therapeutics Inc. for an undisclosed amount. Through this acquisition, Eli Lilly and Company sought to reinforce its cardiometabolic and genetic medicine portfolio by incorporating Verve Therapeutics Inc.’s in vivo gene-editing therapies, supporting the advancement of one-time treatment approaches for individuals with elevated cardiovascular risk and chronic cholesterol-related conditions. Verve Therapeutics Inc. is a US-based biotechnology company focused on developing CRISPR-based gene-editing therapeutics.
Major companies operating in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market are Novartis AG, AstraZeneca PLC, Beam Therapeutics Inc., CRISPR Therapeutics AG, Sana Biotechnology Inc., Wave Life Sciences Ltd., Editas Medicine Inc., EditCo Bio Inc., Cellectis S.A., Metagenomi Inc., Arbor Biotechnologies Inc., Intellia Therapeutics Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Korro Bio Inc., Scribe Therapeutics Inc., Allogene Therapeutics Inc., Prime Medicine Inc.
North America was the largest region in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
This product will be delivered within 1-3 business days.
The clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market size is expected to see rapid growth in the next few years. It will grow to $0.36 billion in 2030 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period can be attributed to the expansion of personalized medicine and gene-based therapies, increasing regulatory approvals for gene editing treatments, rising clinical trial activity for oncology and genetic disorders, continued advancements in in vivo delivery technologies, and increasing investment in next-generation genome engineering platforms. Major trends in the forecast period include growing adoption of precision gene correction therapies for rare genetic conditions, increasing clinical application of programmable nuclease-based therapeutic platforms, expansion of personalized regenerative medicine pipelines, wider use of advanced delivery vectors for targeted gene editing, and increasing integration of high-fidelity gene editing validation and safety assessment frameworks.
The increasing demand for electronic devices is expected to drive the growth of the chiplets market in the coming years. Electronic devices are products or tools that rely on electronic components and technologies to carry out specific functions. Chiplets offer a flexible, cost-efficient, and scalable approach to designing and manufacturing electronic devices, helping address the increasing complexity and performance requirements of modern technologies. For instance, in May 2023, according to the Japan Electronics and Information Technology Industries Association, a Japan-based trade association, consumer electronics production amounted to $2.17 trillion (¥32,099 million) in May 2023, compared with $1.71 trillion (¥25,268 million) in May 2022. Furthermore, in February 2023, according to Uswitch Limited, a UK-based financial conduct authority, there were 71.8 million mobile connections in the UK beginning in 2022. The UK population is projected to reach 68.3 million by 2025, with 95% of the population, or approximately 65 million people, expected to own a smartphone. Therefore, the rising demand for electronic devices is driving the growth of the chiplets market.
Key companies operating in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market are focusing on developing innovative therapies, such as ex vivo gene-editing therapy, to treat inherited genetic disorders and improve long-term patient outcomes. Ex vivo gene-editing therapy is a treatment approach in which a patient's cells are removed from the body, genetically modified or corrected in a laboratory using gene-editing technologies such as CRISPR/Cas9, and subsequently infused back into the patient to help treat or potentially cure diseases by addressing the underlying genetic defect. For example, in January 2024, Vertex Pharmaceuticals, a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for CASGEVY (exagamglogene autotemcel [exa-cel]) for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older. CASGEVY is a one-time CRISPR/Cas9 gene-edited cell therapy designed to address the underlying genetic cause of TDT and reduce the need for chronic blood transfusions. The approval followed the earlier FDA approval of CASGEVY for sickle cell disease and represented a significant advancement in the use of genome-editing therapeutics for inherited blood disorders. In addition, Vertex established a network of authorized treatment centers across the US to support the administration of CASGEVY to eligible patients requiring specialized stem cell transplantation procedures.
In July 2025, Eli Lilly and Company, a US-based pharmaceutical and healthcare company, acquired Verve Therapeutics Inc. for an undisclosed amount. Through this acquisition, Eli Lilly and Company sought to reinforce its cardiometabolic and genetic medicine portfolio by incorporating Verve Therapeutics Inc.’s in vivo gene-editing therapies, supporting the advancement of one-time treatment approaches for individuals with elevated cardiovascular risk and chronic cholesterol-related conditions. Verve Therapeutics Inc. is a US-based biotechnology company focused on developing CRISPR-based gene-editing therapeutics.
Major companies operating in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market are Novartis AG, AstraZeneca PLC, Beam Therapeutics Inc., CRISPR Therapeutics AG, Sana Biotechnology Inc., Wave Life Sciences Ltd., Editas Medicine Inc., EditCo Bio Inc., Cellectis S.A., Metagenomi Inc., Arbor Biotechnologies Inc., Intellia Therapeutics Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Korro Bio Inc., Scribe Therapeutics Inc., Allogene Therapeutics Inc., Prime Medicine Inc.
North America was the largest region in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Characteristics
3. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Supply Chain Analysis
4. Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Trends And Strategies
5. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Analysis Of End Use Industries
7. Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Total Addressable Market (TAM) Analysis for the Market
9. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Segmentation
10. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Regional And Country Analysis
11. Asia-Pacific Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
12. China Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
13. India Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
14. Japan Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
15. Australia Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
16. Indonesia Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
17. South Korea Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
18. Taiwan Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
19. South East Asia Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
20. Western Europe Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
21. UK Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
22. Germany Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
23. France Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
24. Italy Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
25. Spain Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
26. Eastern Europe Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
27. Russia Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
28. North America Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
29. USA Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
30. Canada Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
31. South America Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
32. Brazil Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
33. Middle East Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
34. Africa Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market
36. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Competitive Landscape And Company Profiles
37. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Other Major And Innovative Companies
41. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:
1) By Editing Platform: Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9; Base Editing; Prime Editing; Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 122) By Disease Target: Sickle Cell Disease And Beta Thalassemia; Cancer Immunotherapy; Hereditary Blindness; Duchenne Muscular Dystrophy; Cardiovascular Disease
3) By Delivery Method: Ex Vivo Cell Engineering; In Vivo; Direct Injection
4) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations; Gene Therapy Startups
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 (CRISPR-Cas9): In Vivo Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Gene Editing Therapeutics; Ex Vivo Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Gene Editing Therapeutics; Viral Vector Based Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Therapeutics; Non Viral Delivery Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Therapeutics2) By Base Editing: Cytosine Base Editing Therapeutics; Adenine Base Editing Therapeutics; Ribonucleic Acid Guided Base Editing Therapeutics; Precision Base Editing Therapeutics
3) By Prime Editing: Deoxyribonucleic Acid Sequence Correction Prime Editing Therapeutics; Insertion And Deletion Prime Editing Therapeutics; Programmable Prime Editing Therapeutics; High Fidelity Prime Editing Therapeutics
4) By Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 (CRISPR-Cas12): Single Stranded Deoxyribonucleic Acid Targeting Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Therapeutics; Multiplex Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Gene Editing Therapeutics; High Specificity Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Therapeutics; Diagnostic And Therapeutic Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Platforms
Companies Mentioned: Novartis AG; AstraZeneca PLC; Beam Therapeutics Inc.; CRISPR Therapeutics AG; Sana Biotechnology Inc.; Wave Life Sciences Ltd.; Editas Medicine Inc.; EditCo Bio Inc.; Cellectis S.A.; Metagenomi Inc.; Arbor Biotechnologies Inc.; Intellia Therapeutics Inc.; Caribou Biosciences Inc.; Mammoth Biosciences Inc.; Korro Bio Inc.; Scribe Therapeutics Inc.; Allogene Therapeutics Inc.; Prime Medicine Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Novartis AG
- AstraZeneca PLC
- Beam Therapeutics Inc.
- CRISPR Therapeutics AG
- Sana Biotechnology Inc.
- Wave Life Sciences Ltd.
- Editas Medicine Inc.
- EditCo Bio Inc.
- Cellectis S.A.
- Metagenomi Inc.
- Arbor Biotechnologies Inc.
- Intellia Therapeutics Inc.
- Caribou Biosciences Inc.
- Mammoth Biosciences Inc.
- Korro Bio Inc.
- Scribe Therapeutics Inc.
- Allogene Therapeutics Inc.
- Prime Medicine Inc.
